The MS-STAT2 study is a Phase III, 3 year multi-centre, randomised, placebo-controlled trial assessing the efficacy of 80mg simvastatin vs. placebo in secondary progressive multiple sclerosis (SPMS). Building upon the promising results of the MS-STAT1 study, it is an academically led study funded through a collaboration of the NIHR HTA, MS Society (UK), National MS Society (US), and the Rosetrees Trust.Here we will provide an update on the trial design and progress, including:The agreed trial extension periodAdaptations to recruitment targets and trial designAn update on trial sites where patients can be referredAn update on current trial progressthomas.williams@nhs.net